# Louisiana Withdraws From DEA Marijuana Rescheduling Proceeding Days Before Hearing > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/louisiana-withdraws-from-dea-marijuana-rescheduling-proceeding-days-before-hearing/ > **Published:** 2026-06-27T02:42:35-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:50:25-04:00 > **Clinical Summary:** Federal cannabis rescheduling proceedings affect clinical authority and research access. Understanding state vs. federal cannabis regulation for medical practice. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchIndustrySafetyMental HealthAnxietyPain Why This Matters Louisiana’s withdrawal from the DEA rescheduling proceeding removes a state voice that could have influenced federal scheduling decisions affecting prescribing authority and patient access to [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). Clinicians need clarity on whether cannabis will remain Schedule I or be rescheduled, as this directly impacts their ability to recommend or prescribe cannabis products and their liability in doing so. The outcome of federal rescheduling will determine insurance coverage, research funding availability, and the legal framework under which patients can access cannabis for qualifying medical conditions. Clinical Summary Louisiana’s withdrawal from the DEA marijuana rescheduling proceeding represents a significant setback in federal cannabis policy reform efforts, occurring just days before a critical hearing that could have influenced the drug’s scheduling status. The state’s decision to exit the process may reflect political or administrative considerations at the state level, but it reduces the combined advocacy voice of states seeking rescheduling and potentially weakens arguments for recognizing cannabis’s medical utility. For clinicians, this development signals continued uncertainty regarding federal cannabis policy, which affects the legal framework under which state [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) programs operate and the ability to conduct robust [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/). The proceedings’ trajectory remains consequential for patients enrolled in state [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) programs, as rescheduling could expand research opportunities, improve insurance coverage, and standardize product quality and safety standards across jurisdictions. Clinicians should monitor the ongoing DEA rescheduling process and maintain awareness of how any eventual federal policy changes may alter the landscape for recommending and discussing cannabis with their patients in regulated medical contexts. Dr. Caplan’s Take “Louisiana’s withdrawal from the DEA proceeding reflects the real tension between state-level medical programs and federal scheduling, but we should be clear that yield improvements in controlled growing environments, while interesting economically, don’t tell us much about clinical efficacy or safety profiles for patients. What we need from the federal level is regulatory clarity so that rigorous human trials can finally happen without the current legal barriers.” Clinical Perspective 💊 Louisiana’s withdrawal from the DEA rescheduling proceeding reflects ongoing tensions between state and federal cannabis policy that directly impact clinical practice. While the state has established a [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) program, federal scheduling remains unchanged, creating a legally complex environment where providers must navigate inconsistent regulations across jurisdictions and limited access to rigorous clinical data. The mention of yield-optimization techniques highlights how agricultural advances may increase cannabis availability and potency, but without corresponding federal research permissions or standardized quality controls, clinicians lack reliable dosing information and purity assurances needed for evidence-based prescribing. Healthcare providers should recognize that despite state-level programs, they remain in a position of significant uncertainty regarding recommendations, liability, and drug interaction monitoring until federal policy and research frameworks evolve. Practically, clinicians should document thoroughly when discussing cannabis with patients, maintain awareness of their state’s specific regulations, and consider referring patients to evidence-based pain management and psychiatric alternatives where evidence is 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Louisiana%20Withdraws%20From%20DEA%20Marijuana%20Rescheduling%20Proceeding%20Days%20Before%20Hearing%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D67478)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D67478)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Louisiana%20Withdraws%20From%20DEA%20Marijuana%20Rescheduling%20Proceeding%20Days%20Before%20Hearing%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D67478)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://themarijuanaherald.com/2026/06/louisiana-withdraws-from-dea-marijuana-rescheduling-proceeding-days-before-hearing/](https://themarijuanaherald.com/2026/06/louisiana-withdraws-from-dea-marijuana-rescheduling-proceeding-days-before-hearing/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).